Actively Recruiting
Defining the Basis of Fibromuscular Dysplasia (FMD)
Led by Icahn School of Medicine at Mount Sinai · Updated on 2025-09-29
600
Participants Needed
1
Research Sites
895 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study has evolved and expanded since its inception. Originally the intent was to establish the functional, molecular and genetic profile of fibroblasts from Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects. While this remains among the objectives, the study has been expanded to undertake a fully powered cross-tissue systems genetics analysis of FMD, and now also the related arteriopathies spontaneous coronary artery dissection (SCAD) and cervical artery dissection (CvAD). The overall objective is to disclose the core biologic mechanisms of these disorders.
CONDITIONS
Official Title
Defining the Basis of Fibromuscular Dysplasia (FMD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of any age who freely agree to participate; for patients under 18 years, consent via parents is required
- Fluency in English or Spanish
- Signed, informed consent
- For FMD, SCAD, or CvAD subjects: clinical diagnosis with standard diagnostic criteria
- For healthy controls: no clinical features of FMD, SCAD, or CvAD and no major ongoing systemic disease including conditions requiring hospitalization, immune suppression, intravenous or injected medications, or causing functional impairment in daily activities
- Healthy controls matched to FMD patients by gender and approximate age within 5 years
You will not qualify if you...
- Patients with co-morbidities reducing life expectancy to one year
- Patients with any solid organ or hematological transplantation or those considered for transplantation
- Active autoimmune disease
- Illicit drug use
- HIV positive status
- Prior malignancy
- Any other form of vascular disease including other arteriopathies, coronary artery disease, or peripheral vascular disease
- Family history of arteriopathy other than FMD, SCAD, or CvAD (e.g., Ehlers-Danlos syndrome)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
Research Team
J
Jason Kovacic, MD, PhD
CONTACT
J
Jeffrey Olin, DO
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here